Volume 5, Issue 10: Managing DAA Failures in Light of New HCV Regimen Approvals (PODCAST)

e-Viral Hepatitis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Hepatitis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

(Volume 5, Issue 10)

Target Audience

Nurses and health care professionals involved in the care of patients with Hepatitis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • Describe the risk of resistance development following unsuccessful HCV therapy
    containing direct acting antivirals (DAAs).
  • Discuss the impact DAA resistance and other negative predictors (eg, cirrhosis) have
    on the effectiveness of newly approved retreatment options.
  • Summarize effective retreatment strategies for patients who have previously failed
    HCV therapy containing a direct acting antiviral.
 
 

 

Additional information
Contact email: 
Course summary
Available credit: 
  • 0.50 ANCC
  • 0.50 Attendance
Course opens: 
11/30/2017
Course expires: 
11/29/2019
Cost:
$0.00

David L. Wyles, MD
Chief
Division of Infectious Diseases
Denver Health Medical Center at the University of Colorado
Denver, Colorado

 
 

Available Credit

  • 0.50 ANCC
  • 0.50 Attendance

Accreditation Period

Course opens: 
11/30/2017
Course expires: 
11/29/2019

Price

Cost:
$0.00
Please login or register to take this course.